Cyclacel Pharmaceuticals Future Growth
Future criteria checks 5/6
Cyclacel Pharmaceuticals is forecast to grow earnings and revenue by 76.3% and 82.9% per annum respectively while EPS is expected to grow by 71.9% per annum.
Key information
76.3%
Earnings growth rate
71.9%
EPS growth rate
| Biotechs earnings growth | 28.4% |
| Revenue growth rate | 82.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 13 Nov 2024 |
Recent future growth updates
Recent updates
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely
Aug 17
Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis
Aug 07Is Cyclacel Pharmaceuticals (NASDAQ:CYCC) In A Good Position To Invest In Growth?
Apr 15Cyclacel CEO Spiro Rombotis - Addressing Cancer Resistance (Video)
Oct 04Cyclacel issues key business objectives for 2021
Jan 11Cyclacel Pharma inks securities purchase agreement for $7M
Dec 22Cyclacel Pharmaceuticals EPS misses by $1.74
Nov 11Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0 | -9 | N/A | N/A | 1 |
| 12/31/2025 | 0 | -9 | N/A | N/A | 1 |
| 12/31/2024 | 0 | -10 | N/A | N/A | 1 |
| 9/30/2024 | 0 | -13 | N/A | N/A | N/A |
| 6/30/2024 | 0 | -18 | -12 | -12 | N/A |
| 3/31/2024 | 0 | -20 | -10 | -10 | N/A |
| 12/31/2023 | 0 | -23 | -16 | -16 | N/A |
| 9/30/2023 | 0 | -25 | -17 | -17 | N/A |
| 6/30/2023 | 0 | -24 | -20 | -20 | N/A |
| 3/31/2023 | N/A | -23 | -21 | -21 | N/A |
| 12/31/2022 | N/A | -21 | -21 | -21 | N/A |
| 9/30/2022 | N/A | -19 | -20 | -20 | N/A |
| 6/30/2022 | N/A | -19 | -19 | -19 | N/A |
| 3/31/2022 | N/A | -20 | -22 | -22 | N/A |
| 12/31/2021 | N/A | -19 | -19 | -19 | N/A |
| 9/30/2021 | N/A | -20 | -15 | -15 | N/A |
| 6/30/2021 | N/A | -18 | -11 | -11 | N/A |
| 3/31/2021 | N/A | -15 | -9 | -9 | N/A |
| 12/31/2020 | N/A | -12 | -8 | -8 | N/A |
| 9/30/2020 | N/A | -8 | -8 | -8 | N/A |
| 6/30/2020 | N/A | -8 | -8 | -8 | N/A |
| 3/31/2020 | N/A | -7 | -9 | -9 | N/A |
| 12/31/2019 | N/A | -8 | -9 | -9 | N/A |
| 9/30/2019 | 0 | -8 | -10 | -10 | N/A |
| 6/30/2019 | 0 | -8 | -9 | -9 | N/A |
| 3/31/2019 | 0 | -8 | -8 | -8 | N/A |
| 12/31/2018 | 0 | -7 | -7 | -7 | N/A |
| 9/30/2018 | N/A | -8 | -7 | -7 | N/A |
| 6/30/2018 | N/A | -14 | N/A | -7 | N/A |
| 3/31/2018 | N/A | -15 | N/A | -6 | N/A |
| 12/31/2017 | N/A | -15 | N/A | -7 | N/A |
| 9/30/2017 | 0 | -16 | N/A | -8 | N/A |
| 6/30/2017 | 0 | -10 | N/A | -10 | N/A |
| 3/31/2017 | 1 | -11 | N/A | -11 | N/A |
| 12/31/2016 | 1 | -12 | N/A | -10 | N/A |
| 9/30/2016 | 1 | -13 | N/A | -10 | N/A |
| 6/30/2016 | 1 | -12 | N/A | -11 | N/A |
| 3/31/2016 | 2 | -13 | N/A | -13 | N/A |
| 12/31/2015 | 2 | -15 | N/A | -14 | N/A |
| 9/30/2015 | 2 | -16 | N/A | -15 | N/A |
| 6/30/2015 | 2 | -18 | N/A | -18 | N/A |
| 3/31/2015 | 2 | -20 | N/A | -19 | N/A |
| 12/31/2014 | 2 | -20 | N/A | -19 | N/A |
| 9/30/2014 | 2 | -18 | N/A | -20 | N/A |
| 6/30/2014 | 1 | -19 | N/A | -16 | N/A |
| 3/31/2014 | 1 | -13 | N/A | -18 | N/A |
| 12/31/2013 | 1 | -20 | N/A | -18 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CYCC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: CYCC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CYCC is expected to become profitable in the next 3 years.
Revenue vs Market: CYCC's revenue (82.9% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: CYCC's revenue (82.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CYCC's Return on Equity is forecast to be high in 3 years time